This is an on-the-media podcast extra.

I'm senior producer Leah Fetter, bringing you an update to a story

Brooke and I worked on together a few years back

when then Wall Street Journal reporter John Careroux published Bad Blood,

his eye-popping expose of Elizabeth Holmes

and her promise to revolutionize the blood testing industry.

There's an opportunity to create a new paradigm, being able to make actionable health

information accessible to people everywhere at the time it matters most.

A decade earlier at the age of 19, Holmes had founded Theranos, a company built on the

claim that its microfluidic technology could facilitate a move from deep vein blood draws

to tests based on a single drop of blood. It promised easier, cheaper, more accessible lab tests.

And it quickly became a Silicon Valley darling.

Theranos is valued greater than, say, Quest Diagnostics or Lab Corp. In 2014, Fortune

magazine ran a now iconic cover story featuring homes. Blonde hair, a black turtleneck,

a deadpan stare into the camera, and the headline,

this CEO is out for blood.

But only 16 months later, Karoo would start publishing damning articles,

and Homestar would come tumbling to the ground.

Two articles published in the Walls-Reed Journal investigated the efficacy and accuracy of the single finger prick blood

test that put Theranos on the math.

Theranos saying it is scaling back its tests after the expose in the Wall Street Journal

claims the company uses its key technology in just one of its tests.

...